Strategic Opportunity Potential partnership or acquisition discussions following the Jun 25, 2026 merger news between Remix Therapeutics and Passage Bio, signaling a broader genetic medicines platform and expanded capability in CNS gene therapies that could open collaboration or co-development avenues.

Clinical Stage Focus Target neurology and neurodegenerative indications with one-time genetic therapies; engage with pharmaceutical and biotech buyers seeking late-stage or clinical-stage assets to bolster their CNS portfolios, especially around progranulin-raising approaches for lysosomal function.

Funding / Scale With revenue in the $25M–$50M range and total funding of $154M, identify cost-effective BD conversations emphasizing risk-sharing, milestone-driven deals, and potential for added capital to accelerate pipeline progression.

Leadership Access Leverage senior leadership presence at industry events and conferences to secure high-touch introductions, sponsor symposiums, or arrange executive dialogues with Will Chou and other executives to accelerate priority discussions on partnerships or licensing.

Genetic Medicine Fit Position as a strategic partner for CROs and specialty contract manufacturers focusing on CNS gene therapies, enabling co-development, manufacturing scalability, and regulatory support as the company advances PBFT02 and related assets.